DeepMed Research

Vorapaxar

Generic Name: Vorapaxar

Brand Names: Zontivity

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₃FN_₂O_₄

CAS Number: 618385-01-6

Unique Ingredient Identifier: ZCE93644N2

Background: Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

Indication: Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.

Associated Conditions: Cardiovascular Events

Clinical Trials

Vorapaxar on Thrombin Generation and Coagulability

Phase 4

Completed

Conditions: Coronary Artery Disease
Peripheral Vascular Disease
Myocardial Infarction

Interventions: Drug: Vorapaxar
Drug: Vorapaxar and Clopidogrel
Drug: Vorapaxar and Aspirin
Drug: Vorapaxar, Aspirin, and Clopidogrel

First Posted Date: 2017-07-02

Last Posted Date: 2022-08-18

Lead Sponsor: Inova Health Care Services

Target Recruit Count: 81

Registration Number: NCT03207451

Locations: 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States

Vorapaxar and Lower Extremity Bypass Grafts

Phase 4

Withdrawn

Conditions: Peripheral Artery Disease

Interventions: Drug: Placebos
Drug: Vorapaxar

First Posted Date: 2016-11-29

Last Posted Date: 2018-01-25

Lead Sponsor: Vanderbilt University

Registration Number: NCT02975583

Vorapaxar in the Human Endotoxemia Model

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Vorapaxar
Other: LPS

First Posted Date: 2016-08-23

Last Posted Date: 2020-01-10

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 16

Registration Number: NCT02875028

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Phase 4

Conditions: Peripheral Arterial Disease

Interventions: Drug: Placebo + background APT + SMT
Drug: Vorapaxar 2.08 mg/d + background APT + SMT.

First Posted Date: 2016-01-21

Last Posted Date: 2018-05-29

Lead Sponsor: North Texas Veterans Healthcare System

Target Recruit Count: 200

Registration Number: NCT02660866

Locations: 🇺🇸
Atlanta Heart Specialists, Atlanta, Georgia, United States
🇺🇸
San Diego VA Medical center, San Diego, California, United States
🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States

and more 9 locations

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus
Myocardial Infarction
Peripheral Arterial Disease

Interventions: Drug: Vorapaxar
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2015-09-14

Last Posted Date: 2020-02-12

Lead Sponsor: University of Florida

Target Recruit Count: 66

Registration Number: NCT02548650

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Vorapaxar
Drug: Aspirin
Drug: Ticagrelor

First Posted Date: 2015-09-10

Last Posted Date: 2020-09-16

Lead Sponsor: University of Florida

Target Recruit Count: 130

Registration Number: NCT02545933

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access

Phase 2

Completed

Conditions: AV Fistula

Interventions: Drug: Vorapaxar sulfate
Drug: Placebo

First Posted Date: 2015-06-19

Last Posted Date: 2019-01-14

Lead Sponsor: Ken Mahaffey

Target Recruit Count: 17

Registration Number: NCT02475837

Locations: 🇺🇸
Stanford Univeristy, Stanford, California, United States

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Placebo
Drug: vorapaxar

First Posted Date: 2015-03-20

Last Posted Date: 2019-03-06

Lead Sponsor: Kirby Institute

Target Recruit Count: 65

Registration Number: NCT02394730

Locations: 🇺🇸
Georgetown University Hospital, Georgetown, Maryland, United States
🇦🇺
Melbourne Sexual Health Centre, Carlton, Victoria, Australia
🇺🇸
Hennepin County Medical Centre, Minneapolis, Minnesota, United States

and more 4 locations

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Phase 2

Completed

Conditions: Cerebral Infarction

Interventions: Drug: Placebo
Drug: Vorapaxar 2.5 mg
Drug: Vorapaxar 1 mg
Drug: Aspirin 75-150 mg

First Posted Date: 2008-05-26

Last Posted Date: 2018-09-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 90

Registration Number: NCT00684515

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Phase 2

Completed

Conditions: Myocardial Ischemia
Atherosclerosis
Myocardial Infarction

Interventions: Drug: Placebo
Drug: Vorapaxar
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2008-05-26

Last Posted Date: 2017-05-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT00684203

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy